Repeatability of bronchial hyperresponsiveness to adenosine-5'-monophosphate (AMP) by a short dosimeter protocol
- PMID: 11312404
- PMCID: PMC1746039
- DOI: 10.1136/thorax.56.5.362
Repeatability of bronchial hyperresponsiveness to adenosine-5'-monophosphate (AMP) by a short dosimeter protocol
Abstract
Background: To study bronchial responsiveness to adenosine 5'-monophosphate (AMP) in population surveys, repeatability of a rapid dosimetric method with quadrupling doses was evaluated.
Methods: Volunteers with symptoms of airway respiratory allergy or asthma were invited for AMP challenges on two occasions. After each dose the fall in forced expiratory volume in one second (FEV(1)) compared with the post-saline value was determined. The cumulative doses of AMP needed to cause a fall in FEV(1) of 20% (PD(20)), 15% (PD(15)), and 10% (PD(10)) were calculated. Agreement was evaluated by means of kappa values. After excluding systematic differences in PD values on two occasions (t test), repeatability of a single estimation of the chosen PD values was calculated and expressed in doubling doses (DD).
Results: In 28 of 76 subjects a PD(20) was estimated on the two visits, in 29 subjects a PD(15) was estimated, and in 32 a PD(10) was obtained. Kappa values for a positive threshold were 0.89 for a cut off level for a 20% fall in FEV(1), 0.78 for a 15% fall in FEV(1), and 0.76 for a fall in FEV(1) of 10%. The PD values did not differ between the two visits and 95% repeatability of a single estimation was +/-1.7 DD for PD(20), +/-2.2 DD for PD(15), and +/-2.4 DD for PD(10). The quadrupling dose method reduced time by 40% in non-hyperresponsive subjects and no adverse effects were observed.
Conclusion: The short dosimeter protocol with quadrupling doses for AMP challenges is a rapid, reproducible tool for estimating bronchial responsiveness in population surveys.
Similar articles
-
Bronchial responsiveness to adenosine 5'-monophosphate (AMP) and methacholine differ in their relationship with airway allergy and baseline FEV(1).Am J Respir Crit Care Med. 2002 Feb 1;165(3):327-31. doi: 10.1164/ajrccm.165.3.2104066. Am J Respir Crit Care Med. 2002. PMID: 11818315
-
Adenosine monophosphate and histamine induced bronchoconstriction: repeatability and protection by terbutaline.Thorax. 1997 Mar;52(3):239-43. doi: 10.1136/thx.52.3.239. Thorax. 1997. PMID: 9093339 Free PMC article. Clinical Trial.
-
Adenosine monophosphate is not superior to histamine for bronchial provocation test for assessment of asthma control and symptoms.Clin Respir J. 2017 Jul;11(4):470-480. doi: 10.1111/crj.12360. Epub 2015 Sep 10. Clin Respir J. 2017. PMID: 26257384
-
Methacholine vs adenosine on intra and extrathoracic airway hyperresponsiveness in patients with cough variant asthma.Allergy. 2008 May;63(5):527-32. doi: 10.1111/j.1398-9995.2007.01589.x. Allergy. 2008. PMID: 18394126 Clinical Trial.
-
Airway responsiveness to indirect challenges in COPD.COPD. 2010 Apr;7(2):133-40. doi: 10.3109/15412551003631741. COPD. 2010. PMID: 20397814 Review.
Cited by
-
Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease.Thorax. 2002 Jul;57(7):649-54. doi: 10.1136/thorax.57.7.649. Thorax. 2002. PMID: 12096211 Free PMC article. Review.
-
Proof of concept study to evaluate step-down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma.Br J Clin Pharmacol. 2011 Jan;71(1):128-31. doi: 10.1111/j.1365-2125.2010.03795.x. Br J Clin Pharmacol. 2011. PMID: 21143509 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources